The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause

Detalhes bibliográficos
Autor(a) principal: Correa, Rafaela Fortes
Data de Publicação: 2021
Outros Autores: Casagrande, Thaís Andrade Costa
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/20074
Resumo: Menopause is a biological process that happens in women, since the ovaries stop producing hormones due to the lack of eggs. This stage of a women’s life can happen at 35 to 60 years, and might cause uncomfortable symptoms and even diseases, worsening the life quality of women. The cessation of ovulation has the consequence of reducing the production of estradiol that causes a change in the immune system, predisposing to inflammatory and infectious diseases. Such predisposition can increase the inflammatory mediators IL-6 and IL-17 in the female organism. Melatonin is a hormone manufactured by the pineal gland at night, since the light can debug the hormone. This hormone regulates the circadian rhythm and an immunomodulator. This immunomodulating function that melatonin has can mediate the synthesis and inhibition of some inflammatory mediators. This review aims to identify if melatonin treatment can reduce the quantity of inflammatory mediators in menopausal women. This analysis was performed through a review, with papers searched in the PubMed, Scielo, ScienceDirect and RBAC databases using the keywords: melatonin, menopause, inflammatory mediator, inflammatory modulation, published in the last 15 years. Analyzing the articles, it was identified that melatonin influences the decrease of inflammatory mediators, which may help to improve the life quality of women that are or will be in menopause. However, it is necessary to search for protocols for the use of melatonin, with prediction of use doses and verification of the effects on the body.
id UNIFEI_5a50eaa2d001d7ede190fe9741232a1a
oai_identifier_str oai:ojs.pkp.sfu.ca:article/20074
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopauseEl papel de la melatonina en la reducción de las citocinas IL-6 y IL-17 en la menopausiaO papel da melatonina na redução das citocinas IL-6 e IL-17 na menopausaMelatoninaMediadores InflamatoriosMenopausiaModulación InflamatoriaIL-6IL-17.MelatoninaIL-6Mediadores InflamatóriosMenopausaModulação InflamatóriaIL-17. MelatoninInflammatory MediatorsMenopauseInflammatory ModulationIL-6IL-17.Menopause is a biological process that happens in women, since the ovaries stop producing hormones due to the lack of eggs. This stage of a women’s life can happen at 35 to 60 years, and might cause uncomfortable symptoms and even diseases, worsening the life quality of women. The cessation of ovulation has the consequence of reducing the production of estradiol that causes a change in the immune system, predisposing to inflammatory and infectious diseases. Such predisposition can increase the inflammatory mediators IL-6 and IL-17 in the female organism. Melatonin is a hormone manufactured by the pineal gland at night, since the light can debug the hormone. This hormone regulates the circadian rhythm and an immunomodulator. This immunomodulating function that melatonin has can mediate the synthesis and inhibition of some inflammatory mediators. This review aims to identify if melatonin treatment can reduce the quantity of inflammatory mediators in menopausal women. This analysis was performed through a review, with papers searched in the PubMed, Scielo, ScienceDirect and RBAC databases using the keywords: melatonin, menopause, inflammatory mediator, inflammatory modulation, published in the last 15 years. Analyzing the articles, it was identified that melatonin influences the decrease of inflammatory mediators, which may help to improve the life quality of women that are or will be in menopause. However, it is necessary to search for protocols for the use of melatonin, with prediction of use doses and verification of the effects on the body.Menopausia ocurre biológicamente en las mujeres, ya que los ovarios dejan de funcionar debido a la falta de óvulos. Esta etapa de la vida puede ocurrir desde los 35 a 60 años y puede traer síntomas incómodos y enfermedades, empeorando la calidad de vida de la mujer. El cese de la ovulación es causado por la reducción en la producción de estradiol que provoca cambios en el sistema inmunológico, predisponiendo a enfermedades infecciosas y inflamatorias. La predisposición puede aumentar la cantidad de mediadores inflamatorios IL-6 y IL-17 en el organismo femenino. La melatonina es una hormona producida por la glándula pineal durante la noche, siendo aclarada por la luz. Esta hormona regula el ciclo circadiano y es un inmunomoduladora. La inmunomodulación actúa en la síntesis y inhibición de algunos mediadores inflamatorios. Este trabajo tiene como objetivo identificar si el tratamiento con melatonina puede reducir la cantidad de mediadores inflamatorios en mujeres menopáusicas. Este análisis se realizó mediante una revisión de artículos buscados en las bases de datos Pubmed, Scielo, Sciencedirect y RBAC para las palabras clave: melatonina, menopausia, mediador inflamatorio, modulación inflamatoria, publicado en los últimos 15 años. De acuerdo con el análisis, pudo identificar que la melatonina puede influir en la reducción de mediadores inflamatorios, contribuyendo a mejorar la calidad de vida de las mujeres que entraran en esa etapa de la vida. Sin embargo, es necesario buscar protocolos para el uso de la melatonina, con predicción de dosis de uso y verificación de los efectos en el organismo.A menopausa é um processo biológico que ocorre em mulheres, em que os ovários cessam seu funcionamento pela falta de óvulos. Esse estágio da vida pode ocorrer dos 35 até 60 anos, podendo trazer sintomas desconfortáveis e doenças, piorando a qualidade de vida da mulher. O cessar da ovulação tem como consequência a redução da produção do estradiol que causa alteração no sistema imunológico predispondo a doenças infecciosas e inflamatórias. Tal predisposição pode aumentar os níveis de os mediadores inflamatórios IL-6 e IL-17 no organismo feminino. A melatonina é um hormônio produzido pela glândula pineal durante o período noturno, sendo depurada na presença de luz. Este hormônio regula o ciclo circadiano e é imunomodulador. Essa imunomodulação da melatonina atua na sintetização e inibição de alguns mediadores inflamatórios. Este trabalho tem como objetivo identificar se o tratamento de melatonina pode reduzir a quantidade de mediadores inflamatórios em mulheres na menopausa. Esta análise foi realizada por meio de uma revisão com artigos pesquisados nas bases de dados Pubmed, Scielo, Sciencedirect e RBAC pelas palavras-chave: melatonin, menopause, inflammatory mediator, inflammatory modulation, publicado nos últimos 15 anos. A partir das análises dos artigos foi identificado que a melatonina influencia na redução dos mediadores inflamatórios, podendo auxiliar na melhora da qualidade de vida das mulheres que estão ou que vão entrar na menopausa. Porém, é necessário a busca de protocolos de uso de melatonina, com previsão de doses de uso e verificação dos efeitos no organismo. Research, Society and Development2021-09-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2007410.33448/rsd-v10i12.20074Research, Society and Development; Vol. 10 No. 12; e63101220074Research, Society and Development; Vol. 10 Núm. 12; e63101220074Research, Society and Development; v. 10 n. 12; e631012200742525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/20074/17975Copyright (c) 2021 Rafaela Fortes Correa; Thaís Andrade Costa Casagrandehttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessCorrea, Rafaela FortesCasagrande, Thaís Andrade Costa2021-11-14T20:26:51Zoai:ojs.pkp.sfu.ca:article/20074Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:49.464684Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
El papel de la melatonina en la reducción de las citocinas IL-6 y IL-17 en la menopausia
O papel da melatonina na redução das citocinas IL-6 e IL-17 na menopausa
title The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
spellingShingle The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
Correa, Rafaela Fortes
Melatonina
Mediadores Inflamatorios
Menopausia
Modulación Inflamatoria
IL-6
IL-17.
Melatonina
IL-6
Mediadores Inflamatórios
Menopausa
Modulação Inflamatória
IL-17.
Melatonin
Inflammatory Mediators
Menopause
Inflammatory Modulation
IL-6
IL-17.
title_short The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
title_full The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
title_fullStr The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
title_full_unstemmed The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
title_sort The role of melatonin in reducing the cytokines IL-6 and IL-17 in menopause
author Correa, Rafaela Fortes
author_facet Correa, Rafaela Fortes
Casagrande, Thaís Andrade Costa
author_role author
author2 Casagrande, Thaís Andrade Costa
author2_role author
dc.contributor.author.fl_str_mv Correa, Rafaela Fortes
Casagrande, Thaís Andrade Costa
dc.subject.por.fl_str_mv Melatonina
Mediadores Inflamatorios
Menopausia
Modulación Inflamatoria
IL-6
IL-17.
Melatonina
IL-6
Mediadores Inflamatórios
Menopausa
Modulação Inflamatória
IL-17.
Melatonin
Inflammatory Mediators
Menopause
Inflammatory Modulation
IL-6
IL-17.
topic Melatonina
Mediadores Inflamatorios
Menopausia
Modulación Inflamatoria
IL-6
IL-17.
Melatonina
IL-6
Mediadores Inflamatórios
Menopausa
Modulação Inflamatória
IL-17.
Melatonin
Inflammatory Mediators
Menopause
Inflammatory Modulation
IL-6
IL-17.
description Menopause is a biological process that happens in women, since the ovaries stop producing hormones due to the lack of eggs. This stage of a women’s life can happen at 35 to 60 years, and might cause uncomfortable symptoms and even diseases, worsening the life quality of women. The cessation of ovulation has the consequence of reducing the production of estradiol that causes a change in the immune system, predisposing to inflammatory and infectious diseases. Such predisposition can increase the inflammatory mediators IL-6 and IL-17 in the female organism. Melatonin is a hormone manufactured by the pineal gland at night, since the light can debug the hormone. This hormone regulates the circadian rhythm and an immunomodulator. This immunomodulating function that melatonin has can mediate the synthesis and inhibition of some inflammatory mediators. This review aims to identify if melatonin treatment can reduce the quantity of inflammatory mediators in menopausal women. This analysis was performed through a review, with papers searched in the PubMed, Scielo, ScienceDirect and RBAC databases using the keywords: melatonin, menopause, inflammatory mediator, inflammatory modulation, published in the last 15 years. Analyzing the articles, it was identified that melatonin influences the decrease of inflammatory mediators, which may help to improve the life quality of women that are or will be in menopause. However, it is necessary to search for protocols for the use of melatonin, with prediction of use doses and verification of the effects on the body.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-13
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/20074
10.33448/rsd-v10i12.20074
url https://rsdjournal.org/index.php/rsd/article/view/20074
identifier_str_mv 10.33448/rsd-v10i12.20074
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/20074/17975
dc.rights.driver.fl_str_mv Copyright (c) 2021 Rafaela Fortes Correa; Thaís Andrade Costa Casagrande
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Rafaela Fortes Correa; Thaís Andrade Costa Casagrande
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 12; e63101220074
Research, Society and Development; Vol. 10 Núm. 12; e63101220074
Research, Society and Development; v. 10 n. 12; e63101220074
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052788965900288